QT interval

The Cardiac Risk of Chloroquine in Unapproved Indications

Friday, March 27, 2020 - 1:57am

Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.

Key Points: 
  • Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.
  • Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc.
  • Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.
  • This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3.

BIOTELEMETRY, INC. EXPANDS MCOT™ SERVICE TO MONITOR LIFE-THREATENING QT PROLONGATION IN COVID-19 PATIENTS

Wednesday, March 25, 2020 - 1:21pm

As a reminder, MCOT is the most accurate and studied arrhythmia monitoring detection system in the market.

Key Points: 
  • As a reminder, MCOT is the most accurate and studied arrhythmia monitoring detection system in the market.
  • It provides up to 30 days of near real time monitoring without patients needing to leave their homes.
  • The Company is currently implementing this COVID-19 monitoring initiative in several major institutions and physicians have already started using this service.
  • As part of its FDA 510(k) clearance, MCOT has a specific indication for use with patients requiring measurement, analysis and reporting of QT interval.

New FDA Guidance Allows Use of KardiaMobile 6L to Measure QTc in COVID-19 Patients

Monday, March 23, 2020 - 1:00pm

The QTc is a heart rate corrected interval that reflects the integrity of the heart's electrical recharging system.

Key Points: 
  • The QTc is a heart rate corrected interval that reflects the integrity of the heart's electrical recharging system.
  • "We are thankful to the FDA for issuing timely guidance to help expand the availability of our device to assist in the treatment of COVID-19 during this global health emergency."
  • The FDA-cleared KardiaMobile 6L device is the most clinically validated personal ECG solution in the world.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

World Cardiac Safety Services Market Analysis, 2019-2024 - Increased Outsourcing of R&D Activities and Increasing Number of Clinical Trials Drive the Market

Tuesday, December 31, 2019 - 4:30pm

Growth in this industry is driven by the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increased outsourcing of R&D activities, and the increasing number of clinical trials.

Key Points: 
  • Growth in this industry is driven by the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increased outsourcing of R&D activities, and the increasing number of clinical trials.
  • The cardiac safety services market based on the type of service is categorized into ECG/Holter measurement, blood pressure measurement, cardiovascular imaging, thorough QT studies, and other services.
  • By type, the cardiac safety services market is categorized into integrated and standalone services.
  • The integrated services segment accounted for the largest share of the cardiac safety services market.

Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study

Monday, November 4, 2019 - 12:00pm

The goal of the study was to collect the additional QT interval data requested by FDA for the resubmission of the NDA for oliceridine.

Key Points: 
  • The goal of the study was to collect the additional QT interval data requested by FDA for the resubmission of the NDA for oliceridine.
  • The primary endpoint was the placebo-corrected change from baseline in the individual rate-corrected QT interval (QTcI) measured hourly at each of the 24 time points in the study.
  • There were no individual outliers with a rate-corrected change from baseline >60 msec or an absolute QT interval >500 msec.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders.

QTC Care Closes 7 million USD Series-A Financing - Focusing on Introducing Global Top Medical Resources to China and Advancing Health Management Platforms

Friday, April 26, 2019 - 2:27pm

BEIJING, April26, 2019 /PRNewswire/ -- QTC Care has announced the close of around 7 million USD series-A financing.

Key Points: 
  • BEIJING, April26, 2019 /PRNewswire/ -- QTC Care has announced the close of around 7 million USD series-A financing.
  • It is a health care company focusing on introducing the world's top medical resources to the Chinese market and utilizes artificial intelligence to streamline treatment recovery and disease prevention.
  • This funding will be primarily used for the development of Digital Therapeutics (DTx) and building medical network to service insurance companies.
  • Lu Yi, CEO of QTC Care said: "Traditional health and disease management is usually half-baked due to the lack of effective incentive mechanism and human-based management.

The Potential Role of the J-Tpeak Interval in Proarrhythmic Cardiac Safety: Current State of the Science | ACCP/CSRC Position Paper

Tuesday, April 2, 2019 - 1:30pm

Dr. Michael J. Fossler, Jr emphasized, "This important paper demonstrates the potential value of the J-Tpeak interval, which may be a more discerning marker of pro-arrhythmic potential than the QTc interval.

Key Points: 
  • Dr. Michael J. Fossler, Jr emphasized, "This important paper demonstrates the potential value of the J-Tpeak interval, which may be a more discerning marker of pro-arrhythmic potential than the QTc interval.
  • Very soon, new drug developers may be able to use this technique to develop safer pharmaceuticals for patients.
  • To date, QT interval prolongation has been considered to be an imperfect but nonetheless informative proarrhythmic liability biomarker.
  • More recently, attention has focused on another ECG interval, the heart rate-corrected J-Tpeak interval, hoping that it may prove to be a more discerning biomarker of true proarrhythmic liability.